Overview
NICE is unable to make a recommendation on glasdegib with chemotherapy for untreated acute myeloid leukaemia because Pfizer did not provide an evidence submission.
Last reviewed: 2 September 2020
Next review: We will review this decision if the company decides to make a submission.